Validation of the FINE-CKD Model for Future Health Technology Assessments for Finerenone in Patients With Chronic Kidney Disease And Type 2 Diabetes
FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes
Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects
Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.
Increasing Pharmaceutical Copayments: Impact on Asthma Medication Utilization and Outcomes
Even small changes in average copayment for long-term controller asthma medications can result in significant reductions in medication use and increases in healthcare services.
Colony-Stimulating Factor Prescribing Patterns in Patients Receiving Chemotherapy for Cancer
We linked health insurance records to cancer registry data to analyze colony-stimulating factor use, finding wide divergence from that recommended by practice guidelines.
Quality of Clinical and Economic Evidence in Dossier Formulary Submissions
Toward Evidence-based Assessment for Coverage and Reimbursement of Laboratory-based Diagnostic and Genetic Tests
Consensus Guidelines for Specialty Pharmaceuticals: A Best-Practice Approach for Cost-Effective Management
Optimizing Quality of Care and Cost Effectiveness in Treating Allergic Rhinitis in a Managed Care Setting
Incorporating Clinical Outcomes and Economic Consequences into Drug Formulary Decisions: A Practical Approach
Correspondence regarding, "A Cost-Effective Approach to the Use of Selective Serotonin Reuptake Inhibitors in a Veterans Affairs Medical Center"
